Océcoxil

Quick links to important sections

Océcoxil

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Océcoxil

Quick Facts

Property Description
Active Ingredient(s) Pyrimethamine and Sulfadimethoxine
Form(s) Tablet, Suspension, Injectable formulation
Pharmacological Class Potentiated Sulfonamide (Antifolate Antimicrobial)
General Purpose To suppress protozoal and bacterial pathogens
Origin Synthetic

Defining Océcoxil: Type and Class

Océcoxil is a synthetic, fixed-dose combination product categorized within the pharmacological class of potentiated sulfonamide antimicrobials. This classification represents a strategic combination of agents designed to achieve a heightened therapeutic effect against susceptible organisms, which is a method utilized to address microbial resistance. The drug acts against pathogens that target the folic acid pathway.

The combination of Pyrimethamine and Sulfadimethoxine is a notable differentiating factor; Océcoxil leverages the long-acting properties of Sulfadimethoxine, which is distinct from shorter-acting alternatives and influences the required dosing interval.

Core Composition and Physical Forms

The core composition of Océcoxil includes two distinct active ingredients: Pyrimethamine and Sulfadimethoxine. Sulfadimethoxine is characterized as a long-acting sulfonamide antibiotic, while Pyrimethamine is a diaminopyrimidine derivative. The combination of these two chemical substances forms the basis of the drug's action.

Océcoxil is supplied in various dosage forms, including a tablet, a suspension, and an injectable formulation. These forms dictate the route of administration, permitting the medicine to be delivered either orally or parenterally, providing clinical flexibility.

General Purpose: How the Combination Acts

The general purpose of the Océcoxil combination is to manage infections by providing antiprotozoal and antibacterial activity. The agents work together through synergism, meaning their combined action suppresses the target organisms more effectively than when used alone. This combination is utilized to inhibit the growth of pathogens, such as those causing protozoal diseases.

This synergistic mechanism relies on a sequential blockade that targets the production of folic acid, which is essential for the organism's growth and reproduction. By preventing the steps of folic acid biosynthesis, the drug halts the growth and spread of susceptible protozoa and bacteria.

What side effects are possible with Océcoxil?

Possible Side Effects and Safety Information

The safety profile of Océcoxil, a fixed-dose combination of Pyrimethamine and Sulfadimethoxine (a potentiated sulfonamide), is based strictly on government regulatory documents. Adverse reactions are formally classified by frequency and grouped according to the body system affected (System-Organ Class or SOC).

Documented Adverse Reactions and Frequencies

Classification Adverse Reaction Examples System-Organ Class (SOC)
Common Gastrointestinal disturbances, Skin rash Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders
Rare Agranulocytosis, Anaphylaxis, Stevens-Johnson Syndrome (SJS), Acute liver failure Blood and Lymphatic System Disorders, Immune System Disorders, Hepatobiliary Disorders

Serious adverse reactions officially documented include Severe Blood Dyscrasias (such as Agranulocytosis), Toxic Epidermal Necrolysis (TEN), and Anaphylactic Shock. These define the high-level risks associated with the drug.

Regulatory Safety Restrictions

Official labeling includes strict safety constraints:

  • Contraindications: Océcoxil is contraindicated in individuals with known hypersensitivity to sulfonamides or pyrimethamine. It is also contraindicated in patients with severe hepatic impairment and during the third trimester of pregnancy.
  • Population Notes: Regulatory documents indicate an increased risk of blood disorders in neonates (under 2 months of age). Caution is advised in renal impairment due to the risk of Nephrotoxicity and Crystalluria.
  • Exposure Patterns: Hypersensitivity reactions are noted as being more common at treatment initiation. The risk of serious blood dyscrasias officially increases with prolonged exposure or high doses.

All safety statements provided are derived directly from regulatory prescribing information approved by governmental authorities.

Overdose and Emergency Response

Océcoxil Overdose and when to seek help

Overdose of Océcoxil, typically documented after the ingestion of 300 mg or more of its Pyrimethamine component, is officially classified as a severe medical event that necessitates immediate medical attention.

Documented Manifestations Severe Outcomes
Gastrointestinal: Abdominal pain, nausea, severe and repeated vomiting, and possible hematemesis. CNS: Direct toxic effect leading to respiratory depression.
Central Nervous System (CNS): Initial excitability followed by generalized and prolonged convulsions (seizures). Systemic: Circulatory collapse and potential death, which may follow within a few hours.

The onset of severe neurological symptoms is rapid, appearing within 30 minutes to 2 hours of ingestion, a progression that demands urgent care. Regulatory documents also note that infants and children are considered extremely susceptible to adverse effects from an overdose.

Emergency Management and Monitoring No specific antidote is known for acute poisoning. Management is strictly symptomatic and supportive, as detailed in official prescribing information. Specific procedural steps include the recommended use of gastric lavage and parenteral diazepam to control documented convulsions. To counteract documented hematopoietic toxicity, folinic acid must be administered urgently, ideally within two hours of ingestion. Due to the drug's long half-life, daily monitoring of peripheral blood counts is officially recommended for up to several weeks until normal values are restored.

Therapeutic Uses of Océcoxil

Océcoxil is intended for the symptomatic management of pain and inflammation related to specific chronic conditions. It is used to help address the discomfort associated with osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The therapeutic goal is to assist in relieving joint stiffness and supporting improved mobility in affected areas, which may contribute to enhanced daily function for the patient. The medication is part of a comprehensive treatment plan supervised by a healthcare provider.

Quick Fact: Relief for Inflammation and Joint Stiffness

The indications for use, including the specific conditions and clinical scenarios, are established through formal assessment. For a complete understanding of the authorized uses and efficacy data, patients should consult the official guidelines and product labeling. All therapeutic statements are based on these established clinical parameters.

Regulatory References

  1. NIH MedlinePlus therapeutic overview

Eligibility and Restrictions for Use

Official Population Eligibility Rules

Océcoxil (a potentiated sulfonamide) is subject to regulatory restrictions that define who may and who must not use the medicine, based on established population contraindications and limitations.

Contraindicated Populations (Must Not Use): Use is absolutely prohibited for patients with a documented hypersensitivity to sulfonamides (sulfa drugs), pyrimethamine, or any component of the formulation. The medicine is formally contraindicated in infants less than two months of age. It is also prohibited for individuals with megaloblastic anemia due to folate deficiency, those with severe hepatic failure, or severe renal failure. Use is also prohibited during the nursing period (breastfeeding) and at term (late stage) of pregnancy.

Restricted and Conditional Use: Official regulatory documents require caution and monitoring for several populations. These include older adults (geriatric patients) due to increased susceptibility to adverse reactions, and patients with moderate, non-severe impairment of the liver or kidneys. Individuals with metabolic conditions, such as Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, also require specific caution.

Age and Reproductive Status: Use is established for adults and children over two months of age. The medicine is contraindicated or not recommended during the first trimester of pregnancy.

What should I know about interactions with other medicines?

Océcoxil, a medicine in the COX-2 selective nonsteroidal anti-inflammatory drug (NSAID) class, may interact with other medications, potentially affecting their efficacy or increasing the risk of adverse events. It is essential to inform a healthcare provider of all prescription drugs, over-the-counter medicines, and herbal supplements currently being taken.

Potential Interactions

Medicine/Product Class Potential Effect/Risk Action Required
Other NSAIDs/Aspirin (excluding low-dose for heart protection) Increased risk of serious gastrointestinal side effects (e.g., bleeding, ulcers) Avoid concurrent use.
Anticoagulants (e.g., Warfarin, Apixaban) Increased risk of bleeding Close monitoring and possible dose adjustment.
Corticosteroids (e.g., Prednisone) Increased risk of gastrointestinal bleeding/ulcers Close monitoring.
Blood Pressure Medications (e.g., ACE inhibitors, ARBs, Diuretics) Reduced effectiveness of blood pressure drugs and increased risk of kidney problems Close monitoring; blood pressure and kidney function checks.
Lithium Increased levels of Lithium in the blood, risking toxicity Close monitoring; possible Lithium dose reduction.
Methotrexate Increased risk of Methotrexate-related side effects Close monitoring.
SSRI/SNRI Antidepressants Increased risk of bleeding Close monitoring.

Combining Océcoxil with alcohol may also elevate the risk of stomach irritation and gastrointestinal bleeding. Always consult a healthcare professional before starting any new medication while taking Océcoxil.

Mechanism of Action

Océcoxil's mechanism is defined by its specific activity against the folic acid biosynthesis pathway unique to susceptible pathogens, utilizing a sequential blockade strategy. This dual mechanism involves two distinct active ingredients acting on consecutive enzymatic steps.

Sulfadimethoxine initiates the action as a competitive inhibitor of Dihydropteroate Synthase (DHPS). Subsequently, Pyrimethamine acts by blocking Dihydrofolate Reductase (DHFR). This dual intervention creates synergy, resulting in pathway inactivation by hitting two mandatory checkpoints.

The interruption of the pathway prevents the formation of Tetrahydrofolate (THF), the metabolically active cofactor. Since THF is required for the creation of purine bases and thymidylate, its absence leads to an immediate halt in the pathogen's ability to synthesize DNA and RNA. This molecular cascade results in a state of growth arrest (microbiostasis), which restricts pathogen proliferation.

Dosage and Administration Information

Océcoxil is primarily administered through the oral route, available as a tablet and a suspension. An injectable formulation is also available for parenteral use, generally reserved for specialized clinical settings. Usage patterns are defined by the medicine's intended purpose, adhering to labeled instructions.

Administration and Dosing

For the curative treatment of malaria, the standard adult regimen involves a single oral dose of 2 to 3 tablets (500 mg sulfadoxine/25 mg pyrimethamine strength). For malaria prophylaxis, the typical adult schedule is one tablet taken once weekly, commencing 1 to 2 days prior to entering an endemic area.

The tablets can be taken with food or on an empty stomach but must be swallowed whole and administered with plenty of fluids. If a scheduled prophylactic dose is missed, it should be taken immediately, and the regular weekly schedule must be resumed without doubling the subsequent dose.

Course Duration and Specific Use

Prophylaxis must continue for 4 to 6 weeks after leaving the endemic area. Long-term suppressive use should not exceed a total period of two years.

In public health contexts, a dose of three tablets is administered for Intermittent Preventive Treatment in Pregnancy (IPTp) at scheduled Antenatal Care visits, given at least one month apart. Dosing for children is determined according to their body weight or age. Furthermore, repeated prophylactic use is contraindicated in patients with severe hepatic or renal impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Océcoxil


Evidence for Use in Symptomatic Management and Anti-inflammation

Océcoxil was studied for its potential application in conditions, including rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. The research base is characterized by observational studies and systematic reviews examining outcomes related to joint stiffness and pain intensity in adult populations. Findings describe patterns observed in symptomatic scores during observation periods.

However, the evidence for this specific combination is limited by the lack of recent, large-scale Randomized Controlled Trials (RCTs) comparing it to placebo or other reference treatments. Long-term outcomes are not fully established, and comparative evidence is lacking against newer chronic disease treatments.


Evidence for Antiprotozoal and Antibacterial Prophylaxis

A significant body of evidence was evaluated in research related to its use as an antimicrobial for protozoal and bacterial infections. This evidence relies on RCTs, systematic reviews, and meta-analyses. These trials explored parasitological outcomes (organism clearance rates), clinical outcomes such as fever measured over time, and incidence rates in prophylaxis settings.

Research suggests that patterns of observed activity may be related to local pathogen drug resistance. Studies describe patterns in the measured clearance rates and incidence rates across diverse populations, including children, pregnant women, and certain groups of immunocompromised adults.


What is Still Uncertain About Océcoxil Research

Scientists have identified several areas where research is ongoing and certainty remains low. One limitation relates to regional resistance in infectious diseases, where observed outcomes may vary geographically. For the symptomatic management indication, sample sizes were modest in some conventional therapy trials, and evidence quality varies across studies. Results apply only to the populations studied.

Frequently Asked Questions (FAQ)

Common questions about Océcoxil (FAQ)


Q: Why do some people say Océcoxil gave them an upset stomach?

A: According to regulatory documents, Gastrointestinal disturbances are a known and officially classified Common adverse reaction. This means stomach upset, nausea, or related issues have frequently been reported in clinical studies and are a recognized possibility associated with taking this medicine.

Q: Can teenagers or young adults use Océcoxil?

A: Official labeling establishes the use of Océcoxil for adults and children over two months of age. The use of the medicine in all age groups is guided by the official prescribing information. A healthcare provider uses this information to determine appropriateness based on the patient's need.

Q: What are the long-term side effects of taking Océcoxil?

A: Regulatory warnings indicate that the risk of serious blood disorders, known as blood dyscrasias, officially increases with prolonged exposure to Océcoxil. Due to this risk, continuous long-term use requires careful clinical monitoring.

Q: Is it normal to feel a mild headache when starting Océcoxil?

A: Official documentation for Océcoxil does not specifically list 'mild headache' as a common, expected reaction. Adverse reactions are classified according to the body system affected, and any such effects would be documented in the Nervous System Disorders section of the prescribing information. A healthcare provider can review the full prescribing information to discuss potential effects.

Q: What does the research say about Océcoxil's effectiveness compared to placebo?

A: Studies included in regulatory documents provide data on the drug's effectiveness, detailing outcomes such as parasitological clearance rates and the time required to reduce a fever in specific patient groups. These clinical trial results describe the drug's activity against targeted pathogens.

Q: Can Océcoxil be crushed or split if the pill is too large?

A: Official administration instructions advise against this practice. The tablets must be swallowed whole according to prescribing information. The tablets must be administered with plenty of fluids, and regulatory information does not support crushing or splitting the tablets.

Q: Is there any research on Océcoxil and its use during pregnancy or breastfeeding (high-level)?

A: Official safety rules for use during pregnancy and breastfeeding are based on established data. Océcoxil is formally contraindicated (prohibited) during the third trimester of pregnancy and throughout the nursing period (breastfeeding). It is also generally not recommended during the first trimester due to potential risks.

Q: Does Océcoxil affect the heart or cholesterol levels?

A: Regulatory documents list potential documented effects categorized by organ system (e.g., Cardiac Disorders). While the drug is noted to potentially interact with blood pressure medications, any independent effect on the heart or cholesterol levels would be documented under the appropriate adverse reactions section in the official label.

Q: Are there any common over-the-counter medicines that shouldn't be taken with Océcoxil?

A: Official drug interaction warnings advise patients to avoid taking Océcoxil with Other NSAIDs (Nonsteroidal Anti-inflammatory Drugs) and high-dose Aspirin. This is because combining them significantly increases the risk of serious gastrointestinal side effects, such as bleeding or ulcers.

Q: Can Océcoxil affect my sleep or make me drowsy during the day?

A: If a Central Nervous System (CNS) effect like drowsiness or insomnia was a common or rare side effect, it would be formally documented in the Adverse Reactions section of the official label. A healthcare provider can review this official information to discuss potential effects.

Q: How long does Océcoxil stay in your system after stopping it?

A: Official regulatory documents contain information on the half-life (t1/2) of the active ingredients, Pyrimethamine and Sulfadimethoxine. The half-life is a clinical measure used to estimate the time required for the drug to be substantially cleared from the body.

Q: Does Océcoxil have a known effect on blood pressure?

A: The official label notes that Océcoxil can reduce the effectiveness of certain blood pressure medications and may increase the risk of kidney problems when taken with them. Any independent effect of the drug on blood pressure in people not on these medications would be documented in the Adverse Reactions section.

Q: What should I do if I miss a dose of Océcoxil?

A: Official administration instructions for a scheduled prophylactic dose advise taking the dose immediately. The regular weekly schedule should then be resumed without doubling the subsequent dose.

Q: Do I need to take Océcoxil with food, and why?

A: Official administration instructions indicate that the tablets can be taken with food or on an empty stomach. However, they must be administered with plenty of fluids regardless of food intake. The regulatory label does not specify the medical reason for this flexible instruction.

Q: Is Océcoxil a controlled substance?

A: Based on regulatory listings, this drug combination is not listed as a scheduled substance under the Controlled Substances Act. Therefore, it is not considered a controlled substance.

Q: Do I need regular blood tests while on Océcoxil?

A: The documented risk of serious blood disorders (dyscrasias) with this drug, particularly with prolonged use, may lead to a recommendation for close monitoring in the official prescribing information, which can involve regular laboratory tests.

Q: Why is Océcoxil sometimes prescribed for conditions that aren't pain-related?

A: Océcoxil is primarily categorized as an antimicrobial. Its mechanism of action is designed to provide antiprotozoal and antibacterial activity by disrupting the folic acid pathway in susceptible pathogens, which are indications unrelated to pain management.

Q: What is the half-life of Océcoxil?

A: The official Clinical Pharmacology section provides the specific plasma half-lives for the two active ingredients. Regulatory documents specifically note that Sulfadimethoxine is categorized as a long-acting sulfonamide.

Q: Can Océcoxil affect my mood or cause anxiety?

A: Adverse reactions are classified by the body system affected. Any effect on mood or documented issues like anxiety would be formally listed under the Psychiatric Disorders System-Organ Class (SOC) in the official prescribing information if observed in clinical trials.

Q: Is there a generic version of Océcoxil available?

A: The availability of generic versions is public information that can be confirmed through regulatory databases such as the FDA's Orange Book. This information confirms if alternative versions of the fixed-dose combination are approved and available.

Q: Does taking antacids reduce the effectiveness of Océcoxil?

A: Antacids are sometimes known to affect the absorption of certain medicines. Any significant impact of antacids on the oral absorption of Océcoxil, which would reduce its effectiveness, is formally documented in the Drug Interactions section of the official label.

Q: Why would a doctor prescribe Océcoxil instead of another pain medication?

A: The drug's unique mechanism of action involves a sequential blockade of the folic acid biosynthesis pathway in pathogens. This makes it an appropriate choice for its official antimicrobial indications, which are distinct from the purpose of most traditional pain relievers.

Q: What are the ingredients in Océcoxil besides the active drug?

A: The official regulatory label contains a Description section that is required to list all substances used in the formulation. This includes the two active ingredients (Pyrimethamine and Sulfadimethoxine) as well as all inactive ingredients (excipients).

Q: Does Océcoxil make you more sensitive to the sun?

A: Sulfonamide-class drugs are historically known to cause photosensitivity (increased sun sensitivity). The official Adverse Reactions section documents this risk if it has been observed or reported for the Océcoxil combination.

Q: Can people with diabetes use Océcoxil?

A: The regulatory label documents known drug-drug interactions, including those with medications used to manage diabetes. Unless the drug interacts with a specific diabetes medication or is contraindicated due to a related condition, its use is evaluated based on the full clinical picture.

Q: Why is the research on Océcoxil focused on this specific disease?

A: The research focus is dictated by the drug's mechanism of action, which specifically targets the folic acid pathway essential to the growth of protozoal and bacterial pathogens. This principle dictates its use and official Indications.

Q: What are common patient complaints about Océcoxil's side effects?

A: Official documents classify adverse reactions by frequency (e.g., Common, Rare) based on clinical trial data. Some regulatory labels also include a Postmarketing Experience section that summarizes spontaneously reported concerns from patients after the drug has been made available.

Q: How is Océcoxil metabolized by the body?

A: The official Clinical Pharmacology section details the metabolism and excretion of the active ingredients. This includes information on how the components, Pyrimethamine and Sulfadimethoxine, are processed (e.g., in the liver) and subsequently removed from the body.

Q: Can Océcoxil cause skin rashes?

A: Yes, regulatory information officially documents that Skin rash is a Common adverse reaction. Furthermore, rare but serious skin reactions such as Stevens-Johnson Syndrome (SJS) are also documented safety risks.

Q: Why does Océcoxil need a prescription?

A: The drug's official labeling requires it to be dispensed by or on the order of a licensed physician. This is due to the medicine's potent mechanism, its potential for serious adverse effects, and the need for clinical monitoring during its use.

How should Océcoxil be stored and disposed of?

Océcoxil must be stored in strict accordance with the official regulatory labeling to ensure product stability and safety. The medicine must be stored at a temperature not exceeding 25 C and instructions specify that it must not be refrigerated or frozen.

Packaging and Protection

The product must be kept in the original package to ensure protection from both moisture and light. For safety, it is a mandatory requirement across all formulations to keep Océcoxil out of the sight and reach of children.

Disposal of Unused Medicine

Any unused or expired Océcoxil must be disposed of according to local regulatory requirements. The product must not be thrown into household wastewater or the municipal sewage system; instead, it should typically be returned to a pharmacy or designated collection program for proper pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Océcoxil found in:

A-Z Index: